CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
小分子化合物增强血液系统恶性肿瘤中的 CAR-T 细胞疗法
英文原题：Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies.
查看英文原题
Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞免疫疗法已成功用于血液系统恶性肿瘤患者，但仍需克服若干障碍，例如较高复发率和副作用。解决CAR-T 细胞疗法的局限并提高疗效，是亟待处理的问题。近年来，小分子化合物与CAR-T 细胞疗法联合应用的探索，在临床前和临床研究中取得了有希望的进展。蛋白激酶抑制剂、去甲基化药物、组蛋白去乙酰化酶（HDAC）抑制剂、PI3K抑制剂、免疫调节药物、Akt抑制剂、mTOR抑制剂和Bcl-2抑制剂，与CAR-T 细胞疗法联合时均显示出潜在协同作用。本综述讨论近期这些联合疗法在改善CAR-T 细胞治疗结局方面的应用。
展开英文摘要原文
Although chimeric antigen receptor T cell immunotherapy has been successfully applied in patients with hematological malignancies, several obstacles still need to be overcome, such as high relapse rates and side effects. Overcoming the limitations of CAR-T cell therapy and boosting the efficacy of CAR-T cell therapy are urgent issues that must be addressed.
The exploration of small-molecule compounds in combination with CAR-T cell therapies has achieved promising success in pre-clinical and clinical studies in recent years. Protein kinase inhibitors, demethylating drugs, HDAC inhibitors, PI3K inhibitors, immunomodulatory drugs, Akt inhibitors, mTOR inhibitors, and Bcl-2 inhibitors exhibited potential synergy in combination with CAR-T cell therapy. In this review, we will discuss the recent application of these combination therapies for improved outcomes of CAR-T cell therapy.
论文信息
- 作者
- Cao X、Jin X、Zhang X、Utsav P、Zhang Y、Guo R、Lu W、Zhao M
- 第一作者单位
- First Center Clinic College of Tianjin Medical University, Tianjin, 300192, China.China
- 通讯作者单位
- Department of Hematology, Tianjin First Central Hospital, Tianjin, 300192, China. mingfengzhao@sina.com.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Current treatment options in oncology2023 Mar
- 原文标识
- PubMed 36701037 · DOI 10.1007/s11864-023-01049-4
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →